<DOC>
	<DOCNO>NCT01455389</DOCNO>
	<brief_summary>The goal phase 1 clinical research study find high dose DOTAP : Chol-fus1 safely give combination Tarceva ( erlotinib hydrochloride ) patient NSCLC . The goal phase 2 clinical research study learn combination DOTAP : Chol-fus1 erlotinib hydrochloride help control NSCLC . The safety drug combination also study phase . DOTAP : Chol-fus1 drug help transfer gene call fus1 cancer cell . Researchers think cell without gene may involve development lung cancer tumor . They want find replace gene cell may keep tissue form cancer cell . Erlotinib hydrochloride design block protein tumor cell may control tumor growth survival . This may stop tumor grow .</brief_summary>
	<brief_title>FUS1-nanoparticles Erlotinib Stage IV Lung Cancer</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , assign dose level DOTAP : Chol-fus1 erlotinib hydrochloride base join study . Up 4 dose level study drug combination test . Three ( 3 ) participant enrol dose level . The first group participant receive first dose combination level . After dose give , participant watch 3 week check serious side effect dose level . If participant first group intolerable side effect , 1-2 low dose combination study drug may test . If intolerable side effect see first group , second study group receive next plan dose combination . If intolerable side effect see group , last dose combination test . If enrol Phase II portion , receive high study combination dose tolerated Phase I portion . During Phase II portion study , half participant start receive erlotinib hydrochloride Day 8 Cycle 1 ( +/- 1 day ) . Every odd-numbered participant ( 1 , 3 , 5 , ) enrol Phase II receive delay schedule erlotinib hydrochloride . Study Drug Administration : You receive drug dexamethasone diphenhydramine infusion DOTAP : Chol-fus1 , try low risk possible allergic reaction study drug . Dexamethasone give mouth 24 hour dose DOTAP : Chol-fus1 , vein 30 minute dose . Diphenhydramine also give ( either mouth injection ) 30 minute dose . DOTAP : Chol-fus1 give vein infusion 25-35 minute , Day 1 every 3-week study cycle . You take erlotinib hydrochloride mouth tablet form every day study ( except first week Cycle 1 , enrol Phase II delayed-schedule group ) . Erlotinib hydrochloride tablet take time day . Each erlotinib dose take 8 ounce water , take 1 hour 2 hour meal . The whole dose must take one time . If vomit take tablet ( ) , re-take dose tablet ( ) still see count . Study Tests : Each study cycle 3 week . On Day 1 cycle : - Your vital sign ( blood pressure , heart rate , temperature , breathe rate ) measure . - Urine collect routine test . - You test measure level oxygen blood . On Day 1 Cycle 1 , blood ( 4 tablespoon total ) drawn first dose DOTAP : Chol-fus1 24 hour later ( +/- 4 hour ) , research test check immune system . On Day 2 cycle : - Blood ( 2 teaspoon ) draw routine test test check immune system . - Your vital sign record , ask side effect may . On Day 7 Cycle 1 , tumor biopsy genetic research test . On Day 21 cycle : - You physical exam , include measurement vital sign . - Your medical history record , ask side effect may . - Blood ( 2 teaspoon ) urine collect routine test . On Day 21 every cycle ( Cycles 2 , 4 , 6 , ) , either chest CT PET/CT scan check status disease . Other scan may perform , doctor think need . PK Testing : If Phase 1 one first 6 participant enrol study , blood ( 2 teaspoon time ) drawn pharmacokinetic ( PK ) test . PK test measure amount study drug body different time point . PK sample draw Cycle 1 , follow time : - Day 1 -- dose DOTAP : Chol-fus1 , 15 30 minute dose , 1 , 3 , 6 hour dose - Day 2 - Day 4 - Day 8 - Day 15 Length Treatment : You may continue take study drug long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Long-Term Follow-up : You call study staff every 3 month stop take study drug . The study staff ask question find collect information therapy receive cancer . The call take 15 minute . This investigational study . Erlotinib hydrochloride commercially available FDA approve treatment non-small-cell lung cancer . At time , DOTAP : Chol-fus1 used research . Up 57 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<criteria>1 . Histologically cytologically document nonsmall cell lung cancer ( NSCLC ) . 2 . Stage IV NSCLC , recurrent NSCLC potentially curable radiotherapy surgery whether receive prior chemotherapy . There limit number prior chemotherapy regimens receive . 3 . All patient must tumor specimen adequate analysis EGFR mutation tumor accessible biopsy must consent biopsy . 4 . Karnofsky Performance Status 70 % great , Zubrod Performance Status 1or less . 5 . Age &gt; /= 18 year . 6 . Patients must voluntarily sign inform consent accordance institutional policy . 7 . Negative serum pregnancy test ( serum HCG ) within 7 day study treatment female childbearing potential ( nonchildbearing define great one year postmenopausal surgically sterilize ) . Since betaHCG may falsely elevate result malignancy , woman childbearing potential elevate serum betaHCG level eligible enrollment two Transvaginal Ultrasound ( TVUS ) scan one week apart along serial betaHCG level two week apart inconsistent pregnancy Gynecology consult ensure beta HCG level value high enough see pregnancy TVUS . 8 . Subjects require agree practice effective birth control ( i.e . abstinence , intrauterine device female subject ) study period . 9 . Patients must 4 week great , beyond major surgical procedure thoracotomy , laparotomy joint replacement , must 1.5 week great , beyond minor surgical procedure biopsy subcutaneous tumor , pleuroscopy , etc , must evidence wound dehiscence , active wound infection , comparable major residual complication surgery . 10 . ANC &gt; 1500/mm3 , plt count &gt; 100,000/mm3 11 . PT PTT &lt; 1.25 time institutional upper limit normal . 12 . Adequate renal function document serum creatinine 1.5 mg/dl less , calculated creatinine clearance &gt; 50 ml/min . 13 . Adequate hepatic function document serum bilirubin &lt; 1.5 mg/dl SGOT SGPT 1.5 less x upper limit normal . 14 . Patients asymptomatic brain metastasis treat eligible follow criterion meet : No history seizures precede 6 month . Definitive treatment must complete &gt; /= 4 week prior registration . Subjects must steroids administered brain metastasis related symptom &gt; /= 2 week . Posttreatment image within 2 week registration must demonstrate stability regression brain metastasis . 15 . Stable cardiac condition leave ventricular ejection fraction 40 % great . 16 . FEV1 correct DLCO 35 % &gt; predict . 17 . Absence activate mutation ( Exon 19 deletion Exon 21 L858R mutation ) epidermal growth factor receptor ( EGFR ) pretreatment biopsy tumor . Patients activate EGFR mutation eligible progress follow treatment erlotinib . A pretreatment tumor biopsy must available analysis . If biopsy perform prior entry , biopsy require . 1 . Females pregnant breastfeeding . 2 . `` Study entry '' define date inform consent . Patients receive investigational therapy ( agent FDA approve ) , monoclonal antibody bevacizumab cetuximab , receive radiotherapy skull , spine , thorax pelvis within 30 day entry protocol . Patients permit received palliative radiotherapy extremity provide least 14 day elapse since completion therapy , provide patient receive 10 radiotherapy fraction dose high 30 Gy site , provide skull , spine , thorax pelvis radiotherapy field . 3 . Patients receive standard chemotherapy FDA approve agent within 21 day entry protocol . 4 . Patients receive therapy oral tyrosine kinase inhibitor ( eg , erlotinib ) within 14 day prior entry protocol . 5 . Active systemic viral , bacterial fungal infection require treatment . 6 . Patients brain metastasis ( except allow section 4.1.14 protocol . Neurological assessment use determine brain metastasis . 7 . Patients serious concurrent illness psychological , familial , sociological , geographical , concomitant condition , opinion investigator , would permit adequate followup compliance study protocol . 8 . Prior gene therapy . 9 . History myocardial infarction within 6 month unstable angina within past 6 month . 10 . Patients know HIV positive ineligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Lung Cancer</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>FUS1-nanoparticles</keyword>
	<keyword>DOTAP : Chol-fus1</keyword>
	<keyword>DOTAP : Cholesterol-Fus1 Liposome Complex</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Erlotinib Hydrochloride</keyword>
	<keyword>OSI-774</keyword>
	<keyword>Tarceva</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Decadron</keyword>
	<keyword>Diphenhydramine</keyword>
	<keyword>Benadryl</keyword>
	<keyword>Benylin Cough SyrupPharmacokinetic</keyword>
	<keyword>PK</keyword>
</DOC>